ZNF703 is a zinc finger transcription factor that functions primarily as a transcriptional corepressor through recruitment of histone deacetylases, though it does not bind DNA directly 1. The protein contains six evolutionarily conserved domains, three specific to NET proteins, which are essential for proper subcellular localization and transcriptional repression 1. In cancer contexts, ZNF703 acts as an oncogene across multiple tumor types. Gene amplification at chromosome 8 occurs preferentially in luminal B breast cancers, where ZNF703 forms nuclear complexes with DCAF7, PHB2, and NCOR2, leading to activation of stem cell-related gene expression and increased cancer stem cell populations 2. High ZNF703 expression correlates with poor prognosis in breast 3, colorectal 4, and ovarian cancers 5. Mechanistically, ZNF703 promotes tumor progression by regulating cell proliferation, migration, and invasion 4. In ovarian cancer, ZNF703 interacts with HE4 protein and directly binds to the PEA15 enhancer region to promote transcription 5. Pan-cancer analysis reveals ZNF703 modulates tumor immunity by suppressing CD274, ICAM1, and CXCL3 expression, potentially facilitating immune escape 6. These findings establish ZNF703 as both a prognostic biomarker and potential therapeutic target.